Blockade of the acute activation of mTOR complex 1 decreases hypertrophy development in rats with severe aortic valve regurgitation.
|Auteur(s):||Drolet, Marie-Claude; Desbiens-Brassard, Vincent; Roussel, Élise; Tu, Véronique; Couët, Jacques; Arsenault, Marie|
|Résumé:||Background : Hypertrophy (H) is an adaptive response of the heart to a hemodynamic overload. Severe left ventricular (LV) volume overload (VO) from valve regurgitations (aortic (AR) or mitral regurgitation) leads to eccentric LVH. Increased protein turnover is a major event during development of LVH and the mechanistic target of rapamycin (mTOR) is a key molecule for its control. The role of mTOR inhibition in the development of LVH using rapamycin for relatively short periods of time (days to a few weeks) has been studied in the past in pressure overload models but not in VO models. We investigated if mTOR pathway was activated during LVH development in a model of severe VO (AR) in rats and if a rapamycin treatment can slow heart remodeling in this situation. Methods and Results : Male rats with severe AR were studied acutely at 2 days, at 8 weeks (compensated phase) and 6 months (late phase) after VO induction. mTOR complex (mTORC) 1 (ribosomal S6 protein phosphorylation) was activated early after AR induction but not later in the disease whereas mTORC2 activity levels (Akt phosphorylation at Ser473) remained stable. We observed that a moderate dose of rapamycin (2 mg/kg/day; orally) for 8 weeks prevented severe LVH caused by AR (−46 %: p < 0.001). Rapamycin treatment specifically inhibited LV mTORC1 without altering mTORC2 activity at 8 weeks. Rapamycin also prevented cardiac myocyte hypertrophy caused by AR. Conclusion : Rapamycin slows hypertrophy in LV VO by inhibiting early activation of mTORC1 without modulating mTORC2.|
|Type de document:||Article de recherche|
|Date de publication:||20 août 2015|
|Date de la mise en libre accès:||16 novembre 2017|
|Version du document:||VoR|
|Licence Creative Commons:||https://creativecommons.org/licenses/by/4.0|
|Ce document a été publié dans:||SpringerPlus, Vol. 4 (1), 1–13 (2015)|
|Autre version disponible:||10.1186/s40064-015-1230-1|
|Collection :||Articles publiés dans des revues avec comité de lecture|
Tous les documents dans CorpusUL sont protégés par la Loi sur le droit d'auteur du Canada.